OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates No Shareholder Action Required at This Time BETHLEHEM, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has notified the Company of its intent to nominate two candidates, including the fund’s founder, Rishi Bajaj, to stand for election to the Company’s Board of Directors (the “Board”) at its 2026 Annual ...
OraSure to Participate in Upcoming Investor Conference BETHLEHEM, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference: Stephens Annual Investment Conference on Wednesday, November 19, with a Q&A session scheduled for 10 a.m. CT A live webcast and replay of the Q&A session will be available on the investor relations page of OraSure’s website at . About OraSure Technologies, Inc. OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionabl...
OraSure Announces Third Quarter 2025 Financial Results BETHLEHEM, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended September 30, 2025. “In Q3 we delivered $27.1 million of revenue. While some of our customers continue to experience elevated levels of uncertainty related to funding for public health programs and research, we remain confident in our opportunities to return to growth in 2026, driven by divers...
OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain business developments for 5 p.m. ET on November 5, 2025. A webcast of the conference call will be available on the investor relations page of OraSure’s website at . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webca...
OraSure Technologies Appoints Steven K. Boyd to its Board of Directors Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective OraSure Board Has Added Three New Independent Directors in the Past Three Years Mara Aspinall to Step Down from the Board; Jack Kenny Appointed as Chair of the Board BETHLEHEM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announc...
OraSure Announces Second Quarter 2025 Financial Results BETHLEHEM, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025. “Our Q2 results were consistent with our expectations. We are making significant progress on our initiatives to expand our product portfolio, including launching our novel blood collection device for proteomic research in July. We are also staying closely aligned with our custome...
OraSure Appoints Anne Messing as Chief Commercial Officer BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer. Ms. Messing brings more than 25 years of commercial leadership experience across the healthcare industry, including in life sciences, diagnostics, and clinical laboratory services, with a proven track record of driving growth, building high-performing sales teams, and tra...
OraSure to Announce Second Quarter 2025 Financial Results and Host Earnings Call on August 5th BETHLEHEM, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2025 financial results and certain business developments for 5 p.m. ET on August 5, 2025. A webcast of the conference call will be available on the investor relations page of OraSure’s website at . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webca...
OraSure Launches Novel Blood Collection Device for Proteomic Research The device has the potential to transform proteomic discovery through extended protein stabilization and a simplified workflow for research BETHLEHEM, Pa., July 10, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the launch of its HEMAcollect™●PROTEIN product to meet the evolving needs of proteomic researchers. The product, developed by OTI subsidiary DNA Genotek, is an evacuated blood colle...
OraSure Announces First Quarter 2025 Financial Results BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2025. “Our Q1 results were consistent with our expectations. Our customers continue to demonstrate their preference for our differentiated products in delivering on their important health objectives, even while uncertainty remains elevated related to government funding sources for some ...
OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business developments for 5 p.m. ET on May 7, 2025. A webcast of the conference call will be available on the investor relations page of OraSure’s website at . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will b...
OraSure Announces $40 Million Stock Repurchase Program BETHLEHEM, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that its Board of Directors has authorized the repurchase of up to $40 million of its common stock over the next twenty-four months, which will be funded from cash on hand. The Company may repurchase the shares through various methods in compliance with applicable state and federal securities laws. The amount and timing of sha...
Four Directors at Orasure Technologies Inc bought 197,284 shares at between 3.060USD and 3.173USD. The significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...
OraSure Reports Fourth Quarter 2024 Financial Results BETHLEHEM, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2024. “Our Q4 revenue was consistent with our expectations, including 10% growth in our core revenue. We continue to see signs of gradual recovery in our key end markets, and we are diversifying our business by expanding our product portfolio and adding new customers, offset by eleva...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.